4,080,296 Shares in Tyra Biosciences, Inc. (NASDAQ:TYRA) Bought by Alta Partners Management Company L.P.

Alta Partners Management Company L.P. acquired a new position in Tyra Biosciences, Inc. (NASDAQ:TYRA) in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 4,080,296 shares of the company’s stock, valued at approximately $56,716,000. Tyra Biosciences makes up approximately 89.5% of Alta Partners Management Company L.P.’s investment portfolio, making the stock its biggest holding. Alta Partners Management Company L.P. owned approximately 8.06% of Tyra Biosciences at the end of the most recent quarter.

A number of other institutional investors have also added to or reduced their stakes in the company. FMR LLC raised its holdings in Tyra Biosciences by 0.8% in the third quarter. FMR LLC now owns 3,372,850 shares of the company’s stock worth $79,296,000 after purchasing an additional 26,187 shares in the last quarter. Janus Henderson Group PLC bought a new position in Tyra Biosciences in the third quarter worth $24,994,000. State Street Corp increased its holdings in shares of Tyra Biosciences by 4.4% during the third quarter. State Street Corp now owns 384,732 shares of the company’s stock valued at $9,045,000 after acquiring an additional 16,248 shares in the last quarter. JPMorgan Chase & Co. increased its holdings in shares of Tyra Biosciences by 1.1% during the third quarter. JPMorgan Chase & Co. now owns 368,647 shares of the company’s stock valued at $8,667,000 after acquiring an additional 3,896 shares in the last quarter. Finally, Ally Bridge Group NY LLC increased its holdings in shares of Tyra Biosciences by 2.0% during the third quarter. Ally Bridge Group NY LLC now owns 270,075 shares of the company’s stock valued at $6,349,000 after acquiring an additional 5,415 shares in the last quarter. Institutional investors own 84.14% of the company’s stock.

Tyra Biosciences Price Performance

Tyra Biosciences stock opened at $11.71 on Friday. Tyra Biosciences, Inc. has a one year low of $11.53 and a one year high of $29.60. The stock has a market capitalization of $592.56 million, a PE ratio of -7.27 and a beta of 1.05. The business’s fifty day moving average is $14.22 and its 200 day moving average is $17.90.

Insider Activity at Tyra Biosciences

In related news, Director Nina S. Kjellson sold 7,779 shares of the stock in a transaction on Thursday, January 16th. The stock was sold at an average price of $16.29, for a total transaction of $126,719.91. Following the sale, the director now directly owns 447,857 shares of the company’s stock, valued at $7,295,590.53. This trade represents a 1.71 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Insiders have sold 21,998 shares of company stock valued at $344,818 over the last ninety days. Insiders own 15.40% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on TYRA. HC Wainwright restated a “buy” rating and set a $30.00 price target on shares of Tyra Biosciences in a report on Tuesday, February 18th. UBS Group began coverage on Tyra Biosciences in a report on Tuesday, January 7th. They set a “buy” rating and a $28.00 price target for the company. Six investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $30.50.

About Tyra Biosciences

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.